Effect of sertraline on protein binding of warfarin

Clinical Pharmacokinetics

Volumn 32, Issue SUPPL. 1, 1997, Pages 37-42

  Apseloff, Glen ^a   Wilner, Keith D ^b   Gerber, Nicholas ^a   Tremaine, Larry M ^b  

^a OHIO STATE UNIVERSITY   (United States)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; SERTRALINE; WARFARIN;

ADULT; AREA UNDER THE CURVE; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG METABOLISM; DRUG PROTEIN BINDING; GOOD CLINICAL PRACTICE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PATIENT MONITORING; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0031035097     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700321-00006     Document Type: Review

References (20)

1. Aronoff GR, Bergstrom RF, Pottratz ST, et al. Fluoxetine kinetics and protein binding in normal and impaired renal function. Clin Pharmacol Ther 1984; 36: 138-44
2. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989; 80 (350): 60-75
3. Ronfeld RA, Shaw GL, Tremaine LM. Distribution and pharmacokinetics of the selective 5-HT uptake blocker sertraline in man, rat, and dog [abstract]. Psychopharmacology 1988; 96 Suppl.: 269
4. Serlin MJ, Breckenridge AM. Drug interactions with warfarin. Drugs 1983; 25: 610-20
5. Yacobi A, Stoll RG, Di Santo AR, et al. Intersubject variation of warfarin binding to protein in serum of normal subjects. Res Commun Chem Pathol Pharmacol 1976; 14: 743-6
6. Domenici E, Bertucci C, Salvadori P, et al. Use of a human serum albumin-bused high-performance liquid chromatography chiral stationary phase for the investigation of protein binding: detection of the allosteric interaction between warfarin and benzodiazepine binding sites. J Pharmacol Sci 1991; 80 (2): 164-6
7. Buckley NA, Dawson AH. Drug interactions with warfarin. Med J Aust 1992; 157 (7): 479-83
8. Bannister SJ, Houser VP, Hulse JD, et al. Evaluation for the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin. Acta Psychiatr Scand 1989; 80 (350): 102-6
9. Tremaine LM, Joerg EA. Automated gas chromatographic-electron capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423-9
10. Rettie AE, Koraekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992; 5 (1): 54-9
11. Triplett DA, Harms CS. Procedures for the coagulation laboratory. Chicago, IL: American Society of Clinical Pathologists, 1981: 12-4
12. Ponganis KV, Stanski DR. Factors affecting the measurement of lidocaine protein binding by equilibrium dialysis in human serum. J Pharm Sci 1985; 74: 57-60
13. Lewis RJ, Trager WF. Warfarin metabolism in man: identification of metabolites in urine. J Clin Invest 1970; 49: 907-13
14. Preskorn SH, Lane R. Sertraline 50mg: optimal daily dose in depression. Int Clin Psychopharmacol 1995; 10: 129-41
15. Preskorn SH. Pharmacokinetics of antidepressants: why and how they are relevant to treatment. J Clin Psychiatr 1993; 54 9 Suppl.: 14-34
16. Sudlow G, Birkett DJ, Wade DN. The characterization of two specific binding sites on human serum albumin. Mol Pharmacol 1975; 11: 824-32
17. Banfield C, O'Reilly R, Chan E, et al. Phenylbutazone-warfarin interaction in man: further stereochemical and metabolic considerations. Br J Clin Pharmacol 1983; 16: 669-75
18. Benfield P, Ward A. Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986; 32 (4): 313-4
19. Kelly JG, O'Malley K. Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet 1979; 4: 1-15
20. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997; 32 Suppl. 1: 31-6